AI assistant
Vanda Pharmaceuticals Inc. — Director's Dealing 2009
May 8, 2009
33390_dirs_2009-05-07_f2906ff2-ee57-4c83-bb47-ef36a65fe74d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vanda Pharmaceuticals Inc. (VNDA)
CIK: 0001347178
Period of Report: 2009-05-06
Reporting Person: Irish Stephanie Rast (Sr. VP, Acting CFO/Treasurer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2009-05-06 | Restricted Stock Units | $ | A | 20000 | Acquired | Common Stock (20000) | Direct |
Footnotes
F1: The Restricted Stock Units represented a contingent right to receive a share of the Issuer's common stock which vested upon the Issuer's receipt of approval by the United States Food & Drug Administration of its New Drug Application for Fanapt(TM)(iloperidone) on May 6, 2009.
F2: N/A
F3: On January 20, 2009, the Reporting Person filed a Form 3 which stated that the Reporting Person owned 40,000 shares of Restricted Common Stock which had not vested as of such date. The 20,000 Restricted Stock Units reported herein were included in such aggregate number of securities reported as being owned by the Reporting Person.